Odimma Therapeutics Selected for the France 2030 Export Program

Strengthening Odimma’s International Development Strategy

Odimma Therapeutics has been selected for the France 2030 Export Program, a national initiative designed to support high-potential French innovators in accelerating their international development and strategic growth.

This recognition represents an important milestone for Odimma Therapeutics as the company advances toward the clinical development of ODI-2001, its next-generation personalized immunotherapy platform candidate.

The France 2030 Export Program will support Odimma’s efforts to strengthen international visibility, expand strategic collaborations and accelerate engagement with global biotechnology and oncology ecosystems.

“Being selected for the France 2030 Export Program is both an honour and a strong signal for the company,” said Dr Jean-Marc Limacher, Chairman and Chief Medical Officer of Odimma Therapeutics. “This initiative will support our clinical development roadmap as we prepare for future first-in-human studies and continue to engage with international partners and collaborators.”

The program further reinforces Odimma Therapeutics’ long-term vision of building scalable precision immunotherapy platforms combining AI-driven neoantigen selection, synthetic DNA technologies and personalized oncology innovation.

As the company continues to expand its strategic ecosystem across Europe and internationally, Odimma remains focused on advancing next-generation personalized cancer treatment approaches designed for future clinical deployment.

For more information, please contact us.